ClinicalTrials.gg
CompletedNCT04841369Updated Apr 2, 2024

Phase III Clinical Trial of a Candidate PCV13 in Healthy People Aged 6 Weeks and Above (PICTPCV13i)

A Phase 3 interventional study of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine(CRM197,TT) and 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine in Pneumococcal Infections, Streptococcal Infections and Bacterial Infections, sponsored by CanSino Biologics Inc.. Completed at 1 site in China. Open to participants aged 6 Weeks and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-04-02.

Sponsored by CanSino Biologics Inc. · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
3,420
Allocation
Randomized
Ages
6 Weeks and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies in Pneumococcal Infections with a site in China — 6 open to participants now, 9 under way, 4 of them phase 3. Pneumococcal Infections · China.

Enrollment
Largest of 33
3,420 · median 480
Started
2021
with 2 others
Phase 3
9 of 36
3 open now
Registered
11th of 36
by date
Lead sponsor
3 of 36
CanSino Biologics Inc.

Among the 36 studies in Pneumococcal Infections with a site in China, this one has the largest enrollment of the 33 interventional ones that give a count, is one of 3 that started in 2021, is one of 9 in phase 3, and was the 11th registered.

Pneumococcal Infections

298 studies on the registry are indexed under Pneumococcal Infections; 25 are open to participants now.

Browse Pneumococcal Infections studies →

Open to participants now

6 of the 36 studies in Pneumococcal Infections with a site in China are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 20 Pneumococcal Infections studies recruiting now, 4 (20%) set no upper age limit and 14 (70%) stop at 75 or younger; 14 take children under 18; 16 take healthy volunteers.

This study: 6 Weeks and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Pneumococcal Infections with a site in China, or all of them as a file.
02

Study summary

Streptococcus pneumoniae is a major cause of morbidity and mortality in children worldwide, resulting in up to 1 million pediatric deaths every year.Since the licensure of PCV7 and PCV13,the reported overall decline in invasive pneumococcal disease in hospitalized children younger than 5 years several years is approximately 60% in Western countries.This is a single center,blind, randomized, positive-controlled clinical trial.The purpose of this study is to preliminary evaluate the safety of PCV13i vaccine in subjects at age of 7 months and above,and to investigate the safety and immunogenicity of PCV13i vaccine at age of 2 and 3 months,compared to PCV13.

03

Conditions studied

  • Pneumococcal Infections
  • Streptococcal Infections
  • Bacterial Infections

Keywords

  • PCV13
  • 13 valent Pneumococcal conjugate vaccine
  • Pneumococcal Infections
  • Safety
  • Immunogenicity
04

Who can participate

Ages eligible
6 Weeks and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy subjects of 2 months (minimum 6 weeks), 3 months , 7 months and above;
  • Willing to provide proof of identity;
  • Without vaccination history of pneumococcal vaccine;
  • None-pregnancy or do not plan to pregnancy recently;;
  • Volunteers of 18 years old and above who have the ability to understand clinical studie progress and sign ;
  • Volunteers of 8-17 years old and their guardians who willing sign informed consent;
  • Able to understand and sign the informed consent by their guardians or trustees for the volunteers of 8 years old and below;
  • Able and willing comply with the requirements of the protocol

Exclusion criteria

Exclusion Criteria:

  • Volunteers whose axillary body temperature was >37.0# before vaccination
  • Volunteers who suffered from Congenital malformation or developmental disorder, genetic defect, severe malnutrition, etc;
  • Volunteers who has a history of epilepsy, convulsions or psychosis;
  • Allergic person;
  • Any prior administration of blood products in last 3 month;
  • Any prior administration of other research medicines in last 1 month;
  • Plans to participate in or is participating in any other drug clinical study;
  • Any prior administration of attenuated in last 14 days;
  • Any prior administration of subunit or inactivated vaccines in last 7 days;
  • Had fever before vaccination, Volunteers with temperature >37.0°C on axillary setting;
  • According to the investigator's judgement, the subjects have any other factors that make them unfit to enroll the clinical trial
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
3,420 participants (actual)

Study arms

  • Experimental
    1A

    Subjects received four doses of PCV13i at 2 months of age (At least 6 weeks old)

    Biological: 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine(CRM197,TT)

  • Active comparator
    1B

    Subjects received four doses of PCV13 at 2 months of age (At least 6 weeks old)

    Biological: 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine

  • Experimental
    2A

    Subjects received four doses of PCV13i at 3 months of age

    Biological: 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine(CRM197,TT)

  • Experimental
    3A

    Subject received three doses of PCV13i at 7 to 11 months of age

    Biological: 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine(CRM197,TT)

  • Active comparator
    3B

    Subject received three doses of PCV13 at 7 to 11 months of age

    Biological: 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine

  • Experimental
    4A

    Subjects received two doses of PCV13i at 12 to 23 months of age

    Biological: 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine(CRM197,TT)

  • Active comparator
    4B

    Subjects received two doses of PCV13 at 12 to 23 months of age

    Biological: 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine

  • Active comparator
    5A

    Subjects received one dose of PCV13i at 2 to 5 years old.

    Biological: 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine(CRM197,TT)

  • Active comparator
    5B

    Subjects received one dose of PCV13 at 2 to 5 years old.

    Biological: 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine

Interventions

06

What researchers measure

Primary outcomes

  1. Safety of PCV13i in preventing pneumococcal infections

    Occurance of adverse reactions in all subjects

    Time frame: Within 7 days post each vaccination

  2. Safety of PCV13i in preventing pneumococcal infections

    Occurance of adverse reactions in all subjects

    Time frame: Within 30 days post each vaccination

  3. Immunogenicity of PCV13i in subjects of 2 months (at least 6 weeks) old (Arm 1A-1B)

    Serotype-specific seropositivity rates of Immunoglobulin G GMC concentrations above 0.35ug/ml

    Time frame: 30 days post three doses

  4. Immunogenicity of PCV13i in subjects of 7 to 11 months old (Arm 4A-4B)

    Serotype-specific seropositivity rates of Immunoglobulin G GMC concentrations above 0.35ug/ml

    Time frame: 30 days post three doses

  5. Immunogenicity of PCV13i in subjects of 12 months to 5 years old (Arm 5A, 5B, 6A, 6B)

    Serotype-specific seropositivity rates of Immunoglobulin G GMC concentrations above 0.35ug/ml

    Time frame: 30 days post last dose of vaccination

  6. Immunogenicity of PCV13i in subjects of age 50 years old and above (Arm 6A, 6B, 7A, 7B)

    Serotype-specific seropositivity rates of Immunoglobulin G GMC concentrations above 0.35ug/ml

    Time frame: 30 days post vaccination

Secondary outcomes

  1. Immuogenicity in terms of GMT in subjects of 2 months (at least 6 weeks) old (Arm 1A-1B)

    GMT of serotype-specific OPA antibody with the titer of ≥1:8 ratio

    Time frame: 30 days post three doses

  2. Immunogenicity in terms of IgG concentration in subjects of 2 months (at least 6 weeks) old (Arm 1A-1B)

    Serotype-specific Immunoglobulin G with a concentration of ≥1.0μg/ml

    Time frame: 30 days post three doses

  3. Safety of PCV13i in terms of in subjects of 2 months (at least 6 weeks) old (Arm 1A-1B)

    Occurance of SAE in subjects of this age group

    Time frame: 6 months post one to three doses of vaccination

  4. Immuogenicity in terms of GMT in subjects of 7 to 11 months old (Arm 3A-3B)

    GMT of serotype-specific OPA antibody with the titer of ≥1:8 ratio

    Time frame: 30 days post two doses

  5. Immuogenicity in terms of GMT in subjects of 12 months to 5 years old (Arm 4A, 4B, 5A, 5B)

    GMT of serotype-specific OPA antibody with the titer of ≥1:8 ratio

    Time frame: 30 days post last dose of vaccination

  6. Immunogenicity in terms of IgG concentration in subjects of 7 to 11 months old (Arm 3A-3B)

    Serotype-specific Immunoglobulin G with a concentration of ≥1.0μg/ml

    Time frame: 30 days post two doses

  7. Immunogenicity in terms of IgG concentration in subjects of 12 months to 5 years old (Arm 4A, 4B, 5A, 5B)

    Serotype-specific Immunoglobulin G with a concentration of ≥1.0μg/ml

    Time frame: 30 days post last dose of vaccination

  8. Safety of PCV13i in terms of SAE in subjects of 7 to 11 months old (Arm 3A-3B)

    Occurance of SAE in subjects of this age group

    Time frame: 6 months post two doses

  9. Safety of PCV13i in terms of SAE in subjects of 12 months to 5 years old (Arm 4A, 4B, 5A, 5B)

    Occurance of SAE in subjects of this age group

    Time frame: 6 months post last dose of vaccination

07

Study locations

1 site
  • Neihuang Center for Disease Control and Prevention
    Anyang, Henan 450016, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2021 to primary completion in Mar 2022, 11 months.

Of 81 industry-sponsored phase 3 interventional studies under Pneumococcal Infections, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 23. This study's 11 months is close to that.

Counting every sponsor, half of 82 studies reached it within 13 months; a quarter within 9 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 8, 2021
First posted
Apr 12, 2021
StartActual
Apr 13, 2021
Primary completionActual
Mar 30, 2022
CompletionActual
Sep 20, 2022
Last update
Apr 2, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 2, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04841369
Collaborators
Henan Center for Disease Control and Prevention
Responsible party
Sponsor
First posted
Apr 12, 2021
Start date
Apr 13, 2021
Primary completion
Mar 30, 2022
Completion
Sep 20, 2022
Last update
Apr 2, 2024

Study contacts

Shengli Xia
principal investigator · Henan Province Center for Disease Control and Prevention

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion